

Special Issue

Immunomodulation in Cancer Treatment

Message from the Guest Editor

Immune therapy has revolutionized the treatment of cancer. Much of the impact has been achieved due to immune checkpoint inhibitor (ICI) antibodies targeting the Programmed Death 1 (PD1) axis. It is now clear that, unfortunately, these anti-PD1 ICIs alone are not sufficient to achieve durable tumor control in most patients with cancer. Fortunately, tremendous progress has been made in developing novel approaches to manipulate the immune system to fight cancer. These include cellular therapies, bi-specific T-cell engagers (BiTES) and therapies aimed at targeting immunometabolism, the microbiome or non-T cell populations of immune cells. We are pleased to invite you to contribute to this Special Issue of *Cancers* entitled “Immunomodulation in Cancer Treatment”. This Special Issue will focus on novel approaches to manipulating the immune response against cancer that demonstrate the potential to translate to improved clinical outcomes. For this Special Issue, original research articles and reviews are welcome.

Guest Editor

Dr. Samuel D. Saibil

Departments of Medicine and Immunology, University of Toronto,
Toronto, ON M5S 1A8, Canada

Deadline for manuscript submissions

31 August 2025



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 8.0
Indexed in PubMed



mdpi.com/si/185455

Cancers
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 8.0
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)